Protagonist Therapeutics (PTGX) Total Current Liabilities (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Total Current Liabilities data on file, last reported at $34.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 1.6% year-over-year to $34.5 million; the trailing twelve-month figure through Mar 2026 stood at $34.5 million (down 1.6% YoY), and the FY2025 full-year result was $45.4 million, down 4.13% from the prior year.
• Total Current Liabilities slipped to $34.5 million in Q1 2026, from $45.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $47.4 million in Q4 2024 to a low of $21.3 million in Q4 2023.
• A 5-year average of $36.4 million and a median of $36.8 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities plunged 46.55% in 2023 and surged 122.8% in 2024, its largest moves.
• Tracing PTGX's Total Current Liabilities over 5 years: stood at $31.2 million in 2022, then sank by 31.77% to $21.3 million in 2023, then surged by 122.8% to $47.4 million in 2024, then fell by 4.13% to $45.4 million in 2025, then decreased by 23.97% to $34.5 million in 2026.
• Business Quant data shows PTGX's Total Current Liabilities at $34.5 million in Q1 2026, $45.4 million in Q4 2025, and $44.9 million in Q3 2025.